GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Frazier Lifesciences Acquisition Corp (NAS:FLAC) » Definitions » ROE %

Frazier Lifesciences Acquisition (Frazier Lifesciences Acquisition) ROE % : -14.77% (As of Sep. 2022)


View and export this data going back to 2021. Start your Free Trial

What is Frazier Lifesciences Acquisition ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Frazier Lifesciences Acquisition's annualized net income for the quarter that ended in Sep. 2022 was $-19.12 Mil. Frazier Lifesciences Acquisition's average Total Stockholders Equity over the quarter that ended in Sep. 2022 was $129.46 Mil. Therefore, Frazier Lifesciences Acquisition's annualized ROE % for the quarter that ended in Sep. 2022 was -14.77%.

The historical rank and industry rank for Frazier Lifesciences Acquisition's ROE % or its related term are showing as below:

FLAC's ROE % is not ranked *
in the Diversified Financial Services industry.
Industry Median: 0.53
* Ranked among companies with meaningful ROE % only.

Frazier Lifesciences Acquisition ROE % Historical Data

The historical data trend for Frazier Lifesciences Acquisition's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Frazier Lifesciences Acquisition ROE % Chart

Frazier Lifesciences Acquisition Annual Data
Trend Dec20 Dec21
ROE %
- 3.23

Frazier Lifesciences Acquisition Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
ROE % Get a 7-Day Free Trial Premium Member Only 5.33 2.84 4.19 -3.54 -14.77

Competitive Comparison of Frazier Lifesciences Acquisition's ROE %

For the Shell Companies subindustry, Frazier Lifesciences Acquisition's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Frazier Lifesciences Acquisition's ROE % Distribution in the Diversified Financial Services Industry

For the Diversified Financial Services industry and Financial Services sector, Frazier Lifesciences Acquisition's ROE % distribution charts can be found below:

* The bar in red indicates where Frazier Lifesciences Acquisition's ROE % falls into.



Frazier Lifesciences Acquisition ROE % Calculation

Frazier Lifesciences Acquisition's annualized ROE % for the fiscal year that ended in Dec. 2021 is calculated as

ROE %=Net Income (A: Dec. 2021 )/( (Total Stockholders Equity (A: Dec. 2020 )+Total Stockholders Equity (A: Dec. 2021 ))/ count )
=4.179/( (127.462+131.64)/ 2 )
=4.179/129.551
=3.23 %

Frazier Lifesciences Acquisition's annualized ROE % for the quarter that ended in Sep. 2022 is calculated as

ROE %=Net Income (Q: Sep. 2022 )/( (Total Stockholders Equity (Q: Jun. 2022 )+Total Stockholders Equity (Q: Sep. 2022 ))/ count )
=-19.12/( (131.852+127.072)/ 2 )
=-19.12/129.462
=-14.77 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Sep. 2022) net income data. ROE % is displayed in the 30-year financial page.


Frazier Lifesciences Acquisition  (NAS:FLAC) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Sep. 2022 )
=Net Income/Total Stockholders Equity
=-19.12/129.462
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-19.12 / 0)*(0 / 139.0915)*(139.0915 / 129.462)
=Net Margin %*Asset Turnover*Equity Multiplier
=N/A %*0*1.0744
=ROA %*Equity Multiplier
=N/A %*1.0744
=-14.77 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Sep. 2022 )
=Net Income/Total Stockholders Equity
=-19.12/129.462
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-19.12 / -19.12) * (-19.12 / -9.176) * (-9.176 / 0) * (0 / 139.0915) * (139.0915 / 129.462)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1 * 2.0837 * N/A % * 0 * 1.0744
=-14.77 %

Note: The net income data used here is four times the quarterly (Sep. 2022) net income data. The Revenue data used here is four times the quarterly (Sep. 2022) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Frazier Lifesciences Acquisition ROE % Related Terms

Thank you for viewing the detailed overview of Frazier Lifesciences Acquisition's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Frazier Lifesciences Acquisition (Frazier Lifesciences Acquisition) Business Description

Traded in Other Exchanges
N/A
Address
601 Union Street, Two Union Square, Suite 3200, Seattle, WA, USA, 9810
Frazier Lifesciences Acquisition Corp is a blank check company.
Executives
David Joseph Topper director, officer: Chief Financial Officer C/O GENERAL ATLANTIC SERVICE COMPANY, LP, 55 EAST 52ND STREET, 32ND FLOOR, NEW YORK NY 10055
Krishna R Polu director C/O RAPTOR PHARMACEUTICAL CORP, 7 HAMILTON LANDING, SUITE 100, NOVATO CA 94949
Robert Jr. Baltera director 6275 NANCY RIDGE DRIVE, SUITE 110, SAN DIEGO CA 92121
Carol Giltner Gallagher director C/O ATARA BIOTHERAPEUTICS, INC., 3260 BAYSHORE BOULEVARD, BRISBANE CA 94005
Michael Bigham director 890 WINTER STREET, WALTHAM MA 02451
Deerfield Management Company, L.p. (series C) 10 percent owner, other: Possible Member of 10% Group 345 PARK AVENUE SOUTH, 12TH FLOOR, NEW YORK NY 10010
Deerfield Mgmt L.p. 10 percent owner, other: Possible Member of 10% Group 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Deerfield Partners, L.p. 10 percent owner, other: Possible Member of 10% Group 345 PARK AVENUE SOUTH, 12TH FLOOR, NEW YORK NY 10010
James E Flynn 10 percent owner, other: Possible Member of 10% Group 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Viking Global Investors Lp 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Ole Andreas Halvorsen 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Opportunities Parent Gp Llc 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Rose Sharon Shabet 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Opportunities Illiquid Investments Sub-master Lp 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Opportunities Gp Llc 10 percent owner 55 RAILROAD AVENUE, GREENWICH CT 06830